Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. April 10, 2019. Lisa Stearns.

Executive Summary

A new economic analysis found that targeted drug delivery (TDD) with Medtronic PLC's SynchroMed II drug infusion pump is associated with reduced health-care use and costs for patients with cancer pain compared to conventional medical management alone. See what study investigator Lisa Stearns of the Center for Pain and Supportive Care in Phoenix said about it here.

“The findings suggest that TDD is a cost-saving therapy that should be considered in patients with cancer for whom oral opioids are inadequate or produce intolerable adverse effects and should be expanded as health-care systems transition to value-based models." –Lisa Steans, researcher, Center for Pain and Supportive Care

Click here for a free trial of Medtech Insight


Related Content

Medtronic’s SynchroMed II Infusion Pain Treatment Proves Cost-Effective In Study





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts